Our consultancy provides strategic direction and tactical execution for development of novel pharmaceuticals and medical devices
Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
Gary Novack, Ph.D.
Gary D. Novack, Ph.D., President of PharmaLogic Development, Inc. has decades of experience in successful product development. Together with his team of senior experts, PharmaLogic can help you execute that plan.
In our 25+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
If you don’t know where you are going, any road will get you there.
– Lewis Carroll
The Dry Eye Workshop II (DEWS II) report, sponsored by the Tear Film and Ocular Surface Society, has now been published in the July 2017 issue of The Ocular Surface. There is an introduction, and 10 sub-committee reports, including the Clinical Trials and Regulatory...read more
Dr. Novack provided an update on novel therapies in pharmacotherapies in Ophthalmology Times. He reviews treatments in all phases of clinical development, and those recently approved. This is from anterior (dry eye, glaucoma) to posterior (wet AMD,...read more
Several groups have declared July 2017 as Dry Eye Awareness Month. TFOS DEWS II™ highlights will be presented at a July 12 Congressional Briefing entitled Dry Eye: An Updated Definition, A Greater Impact on Vision Health—co-hosted by TFOS and the Alliance for Eye and...read more